Latest & greatest articles for fluticasone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluticasone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluticasone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluticasone

41. Azelastine hydrochloride plus fluticasone propionate (Dymista) - for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis

Azelastine hydrochloride plus fluticasone propionate (Dymista) - for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis Published 09 December 2013 Product Update azelastine hydrochloride 137micrograms plus fluticasone propionate 50micrograms per actuation nasal spray (Dymista ® nasal spray) (No: 921/13) Meda Pharmaceuticals O8 November 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards (...) and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission azelastine hydrochloride plus fluticasone propionate nasal spray (Dymista ® ) is not recommended for use within NHS Scotland. Indication under review: for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient

Scottish Medicines Consortium2013

42. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial

Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial 23440247 2013 05 09 2013 07 02 2016 12 15 1468-3296 68 6 2013 Jun Thorax Thorax Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old (...) with asthma: a randomised trial. 513-20 10.1136/thoraxjnl-2012-202606 The inhaled corticosteroid fluticasone furoate (FF) in combination with the long-acting β2 agonist vilanterol (VI) is in development for asthma and chronic obstructive pulmonary disease. To assess the safety and tolerability of FF/VI over 52 weeks in patients with asthma. Patients (aged ≥12 years; on inhaled corticosteroid) were randomised (2:2:1) to FF/VI 100/25 µg or FF/VI 200/25 µg once daily in the evening, or fluticasone propionate

EvidenceUpdates2013 Full Text: Link to full Text with Trip Pro

43. Randomized Controlled Trial Comparing Aerosolized Swallowed Fluticasone to Esomeprazole for Esophageal Eosinophilia

Randomized Controlled Trial Comparing Aerosolized Swallowed Fluticasone to Esomeprazole for Esophageal Eosinophilia 23399553 2013 03 05 2013 05 20 2015 11 19 1572-0241 108 3 2013 Mar The American journal of gastroenterology Am. J. Gastroenterol. Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia. 366-72 10.1038/ajg.2012.443 Patients with clinical symptoms of esophageal dysfunction and dense eosinophilic infiltration (...) of the esophageal mucosa are suspected to have eosinophilic esophagitis (EoE). Topical steroids are often used as first-line therapy for EoE, although some patients respond clinically to proton pump inhibitors (PPIs). The purpose of this study was to compare the histological and clinical response of patients with esophageal eosinophilia treated with aerosolized swallowed fluticasone propionate vs. esomeprazole. This prospective single-blinded randomized controlled trial enrolled newly diagnosed patients

EvidenceUpdates2013

44. Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma

Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma Gerzeli S, Rognoni C, Quaglini S, Cavallo MC (...) , Cremonesi G, Papi A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of beclomethasone with formoterol versus fluticasone propionate with salmeterol, for patients with moderate-to-severe

NHS Economic Evaluation Database.2013

45. Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) - For the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema

Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) - For the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Ellipta (fluticasone furoate and vilanterol trifenatate) Inhalation Powder Company

FDA - Drug Approval Package2013

46. Relvar Ellipta - fluticasone furoate / vilanterol

Relvar Ellipta - fluticasone furoate / vilanterol 19 September 2013 EMA/282960/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Relvar Ellipta International non-proprietary name: fluticasone furoate / vilanterol Procedure No. EMEA/H/C/002673/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone (...) +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail info@ema.europa.eu Website www.ema.europa.eu © European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. Product information Name of the medicinal product: Relvar Ellipta Applicant: Glaxo Group Ltd 980 Great West Road Brentford Middlesex TW8 9GS United Kingdom Active substance: Fluticasone furoate / vilanterol trifenatate International Nonproprietary Names: Fluticasone furoate / vilanterol Pharmaco

European Medicines Agency - EPARs2013

47. Chronic obstructive pulmonary disease: fluticasone furoate plus vilanterol

Chronic obstructive pulmonary disease: fluticasone furoate plus vilanterol Chronic obstructiv Chronic obstructive pulmonary disease: e pulmonary disease: fluticasone furoate plus vilanterol fluticasone furoate plus vilanterol Evidence summary Published: 18 June 2013 nice.org.uk/guidance/esnm21 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in June 2013. See summaries of product characteristics (SPCs), British national (...) formulary (BNF) or the MHRA or NICE websites for up- to-date information. Summary Fluticasone furoate/vilanterol (Relvar Ellipta) is a once-daily corticosteroid and long-acting beta 2 agonist combination inhaler, which has been submitted for a marketing authorisation for the symptomatic treatment of adults with chronic obstructive pulmonary disease (COPD) and an exacerbation history despite regular bronchodilator therapy. There are currently no published studies comparing fluticasone furoate/vilanterol

National Institute for Health and Clinical Excellence - Advice2013

48. Fluticasone/formoterol (Flutiform) - in the regular treatment of asthma

Fluticasone/formoterol (Flutiform) - in the regular treatment of asthma Published 08 October 2012 Product Update fluticasone proprionate and formoterol fumarate metered dose inhaler, 50microgram/5microgram, 125microgram/5 microgram 250microgram/10 microgram (flutiform®) (No:736/11) Napp Pharmaceuticals Ltd 07 October 2011 (Issued 7 September, 2012) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic (...) Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission fluticasone proprionate and formoterol fumarate metered dose inhaler (flutiform®) is accepted for use in NHS Scotland. Indication under review: in the regular treatment of asthma where the use of a combination product [an inhaled corticosteroid (ICS) and a long-acting ß 2 agonist (LABA)] is appropriate: ? for patients not adequately controlled on ICS and ‘as required’ inhaled

Scottish Medicines Consortium2012

49. Dymista (azelastine hydrochloride and fluticasone proprionate) Nasal Spray

Dymista (azelastine hydrochloride and fluticasone proprionate) Nasal Spray Drug Approval Package: Dymista (azelastine hydrochloride and fluticasone proprionate) NDA #202236 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Dymista (azelastine hydrochloride and fluticasone proprionate) Nasal Spray, 137 mcg/50mcg Company: Meda Pharmaceuticals, Inc. Application No.: 202236 Approval Date: 05/01/2012 Persons with disabilities having problems accessing

FDA - Drug Approval Package2012

50. Fluticasone furoate and Vilanterol (Breo Ellipta)

Fluticasone furoate and Vilanterol (Breo Ellipta) CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 204275Orig1s000 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 204275 Priority or Standard Standard Submit Date(s) July 11, 2012 Received Date(s) July 12, 2012 PDUFA Goal Date May 12, 2012 Division / Office ODEII/DPARP Reviewer Name(s) Sofia Chaudhry, MD Review Completion Date March 18, 2013 Established Name Fluticasone furoate and Vilanterol (Proposed (...) ) Trade Name Breo Ellipta Therapeutic Class ICS/LABA Applicant GlaxoSmithKline Formulation(s) Orally inhaled Dosing Regimen Once daily Indication(s) 1) Maintenance treatment of airflow obstruction 2) Reduction in exacerbation Intended Population(s) COPD Template Version: March 6, 2009 Reference ID: 3277679Clinical Review Sofia Chaudhry, MD NDA 204275 Breo Ellipta (fluticasone furoate and vilanterol) 2 Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT 9 1.1 Recommendation on Regulatory Action

FDA - Drug Approval Package2012

51. Asthma: fluticasone/formoterol (Flutiform) combination inhaler

Asthma: fluticasone/formoterol (Flutiform) combination inhaler Asthma: fluticasone/formoterol (Flutiform) Asthma: fluticasone/formoterol (Flutiform) combination inhaler combination inhaler Evidence summary Published: 12 October 2012 nice.org.uk/guidance/esnm3 pathways Ov Overview erview Key points from the evidence The content of this evidence summary was up-to-date in October 2012. See summaries of product characteristics (SPCs), British national formulary (BNF), BNF for children (BNFc (...) ) or the MHRA or NICE websites for up-to-date information. Fluticasone/formoterol (Flutiform) is a combination inhaler containing an inhaled corticosteroid (ICS) and a long-acting beta-2 agonist (LABA). It was launched in the UK in September 2012 and is indicated for regular treatment of asthma when a combination inhaler is appropriate: for people whose asthma is not adequately controlled on an ICS and an 'as required' inhaled short-acting beta-2 agonist, or for people whose asthma is adequately controlled

National Institute for Health and Clinical Excellence - Advice2012

52. Fluticasone furoate versus fluticasone propionate for seasonal allergic rhinitis: a review of the clinical and cost-effectiveness

Fluticasone furoate versus fluticasone propionate for seasonal allergic rhinitis: a review of the clinical and cost-effectiveness Fluticasone furoate versus fluticasone propionate for seasonal allergic rhinitis: a review of the clinical and cost-effectiveness Fluticasone furoate versus fluticasone propionate for seasonal allergic rhinitis: a review of the clinical and cost-effectiveness Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Fluticasone furoate versus fluticasone propionate for seasonal allergic rhinitis: a review of the clinical and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2011 Authors' conclusions Two randomized controlled studies showed similar efficacy between

Health Technology Assessment (HTA) Database.2011

53. Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis 21377716 2011 04 04 2011 05 31 2013 11 21 1097-6825 127 4 2011 Apr The Journal of allergy and clinical immunology J. Allergy Clin. Immunol. Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis. 927-34 10.1016/j.jaci.2011.01.037 In clinical trials, only about 60% of subjects report an excellent response to intranasal steroids (...) , suggesting a need to add therapies to intranasal steroids to provide additional efficacy. To determine whether the combination of fluticasone furoate and oxymetazoline is more efficacious than either agent alone, and to determine whether rhinitis medicamentosa develops after treatment. We performed a double-blind, double-dummy, randomized, placebo-controlled parallel study. Sixty patients with perennial allergy were randomized to 4 weeks of once-a-night treatment with fluticasone furoate, oxymetazoline

EvidenceUpdates2011

54. Comparison of the effect of low-dose ciclesonide and fixed-dose fluticasone propionate and salmeterol combination on long-term asthma control

Comparison of the effect of low-dose ciclesonide and fixed-dose fluticasone propionate and salmeterol combination on long-term asthma control 21088114 2011 02 02 2011 03 17 2015 11 19 1931-3543 139 2 2011 Feb Chest Chest Comparison of the effect of low-dose ciclesonide and fixed-dose fluticasone propionate and salmeterol combination on long-term asthma control. 311-8 10.1378/chest.09-1735 Patients with mild persistent asthma constitute about 70% of the asthma population; thus, it is important (...) to know which first-line treatment is best for the management of mild asthma. We compared benefits of first-line treatment with ciclesonide and a combination of fluticasone and salmeterol in patients with mild asthma. Patients aged 12 to 75 years with mild persistent asthma were enrolled in a randomized, double-blind, placebo-controlled study. After run-in, patients were randomized to ciclesonide 160 μg once daily (CIC160), fluticasone propionate/salmeterol 100/50 μg bid (FP200/S100), or placebo

EvidenceUpdates2011

55. Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials

Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials Budesonide/formoterol vs salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials Budesonide/formoterol vs salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials Halpin DM, Gray J, Edwards SJ (...) , Morais J, Singh D CRD summary The review of indirect comparisons concluded that budesonide/formoterol was associated with fewer pneumonia events than salmeterol/fluticasone in patients with chronic obstructive pulmonary disease. The authors' conclusions seem reasonable but reporting limitations mean that cautious interpretation is warranted. Authors' objectives To compare the efficacy of budesonide/formoterol with salmeterol/fluticasone on the incidence of pneumonia adverse events, pneumonia serious

DARE.2011

56. Comparative efficacy of indacaterol 150mug and 300mug versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease: a network meta-analysis

Comparative efficacy of indacaterol 150mug and 300mug versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease: a network meta-analysis Comparative efficacy of indacaterol 150mug and 300mug versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease: a network meta-analysis Comparative efficacy of indacaterol 150mug (...) and 300mug versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease: a network meta-analysis Cope S, Capkun-Niggli G, Gale R, Jardim JR, Jansen JP CRD summary This review concluded that indacaterol was expected to have similar effects on health status and breathlessness to salmeterol/fluticasone and similar effects on health status to formoterol/budesonide. It was also expected to be at least as good as formoterol

DARE.2011

57. Efficacy of fluticasone furoate nasal spray vs. placebo for the treatment of ocular and nasal symptoms of allergic rhinitis: a systematic review

Efficacy of fluticasone furoate nasal spray vs. placebo for the treatment of ocular and nasal symptoms of allergic rhinitis: a systematic review Efficacy of fluticasone furoate nasal spray vs. placebo for the treatment of ocular and nasal symptoms of allergic rhinitis: a systematic review Efficacy of fluticasone furoate nasal spray vs. placebo for the treatment of ocular and nasal symptoms of allergic rhinitis: a systematic review Rodrigo GJ, Neffen H CRD summary The authors concluded (...) that intranasal fluticasone furoate at a dose of 110mcg once daily was effective in improving ocular and nasal symptoms in adolescents and adults with allergic rhinitis. The authors’ conclusions reflect the evidence presented, but it should be noted that not all outcomes appeared to demonstrate clinical significance. Authors' objectives To evaluate the effectiveness of fluticasone furoate nasal spray versus placebo for the treatment of ocular and nasal symptoms in patients with allergic rhinitis. Searching

DARE.2011

58. Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma

Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma 20622031 2010 11 16 2010 12 03 2015 11 19 1535-4970 182 10 2010 Nov 15 American journal of respiratory and critical care medicine Am. J. Respir. Crit. Care Med. Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma. 1221-7 10.1164/rccm.201002-0193OC For children with symptomatic asthma despite low to moderate doses of inhaled corticosteroids (...) , evidence is still lacking whether to add a long-acting bronchodilator or to increase the dose of inhaled corticosteroids. To evaluate whether salmeterol/fluticasone propionate (SFP), 50/100 μg twice a day, is noninferior regarding symptom control compared with fluticasone propionate (FP), 200 μg twice a day Diskus in children with symptomatic asthma. A multicenter, randomized, parallel-group, double-blind study was performed comparing SFP and FP treatment during 26 weeks on asthma control and lung

EvidenceUpdates2011

59. Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease

Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy (...) for chronic obstructive pulmonary disease Dalal AA, Roberts MH, Petersen HV, Blanchette CM, Mapel DW Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of initial maintenance therapy with fluticasone propionate and salmeterol

NHS Economic Evaluation Database.2011

60. Inhaled fluticasone propionate reduces postoperative sore throat, cough, and hoarseness

Inhaled fluticasone propionate reduces postoperative sore throat, cough, and hoarseness 20237046 2010 09 27 2010 10 11 2015 11 19 1526-7598 111 4 2010 Oct Anesthesia and analgesia Anesth. Analg. Inhaled fluticasone propionate reduces postoperative sore throat, cough, and hoarseness. 895-8 10.1213/ANE.0b013e3181c8a5a2 Sore throat is a common complication after surgery. Postoperative cough and hoarseness can also be distressing to patients. We sought to determine the effect of an inhaler steroid (...) on sore throat, cough, and hoarseness during the first 24 hours of the postoperative period. We enrolled 120 women with ASA physical status I or II and term singleton pregnancy who were scheduled for elective cesarean delivery under general anesthesia. Patients were randomized into 2 groups: in the sitting position, group F patients received 500 μg inhaled fluticasone propionate via a spacer device during 2 deep inspirations, after arrival in the operating room, and group C had no treatment

EvidenceUpdates2010